CAS: 782500-75-8; (4S,7S,10R,13R,16S,22S,25S,28S,31S,34S,37S,40S,43S,46S,49S,52S,58S)-4-(((6S,12S,15S,18S,21S,24R,27S,30S)-21-((1H-Indol-3-yl)Methyl)-1-Amino-12-(4-Aminobutyl)-27-((R)-Sec-Butyl)-6-Carbamoyl-1-Imino-18-Isobutyl-15-Isopropyl-24-Methyl-8,11,14,17,20,23,26,29-Octaoxo-31-Phenyl-2,7,10,13,16,19,22,25,28-Nonaazahentriacontan-30-yl)Carbamoyl)-58-(2-((S)-2-Amino-3-(1H-Imidazol-5-yl)Propanamido)Acetamido)-16-(3-Amino-3-Oxopropyl)-7-(4-Aminobutyl)-49-Benzyl-22-(2-Carboxyethyl)-40-(Carboxymethyl)-28-(4-Hydroxybenzyl)-46,52-Bis((S)-1-Hydroxyethyl)-31,34,43-Tris(Hydroxymethyl)-25-Isobutyl-37-Isopropyl-10,13-Dimethyl-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-Octadecaoxo-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56-Octadecaazahenhexacontanedioic Acid

该化合物是一种合成的浸泡物和类似胶囊的浸泡物-1 (GLP-1) 受体激动剂,主要用于管理2型糖尿病,目的是加强葡萄糖依赖的胰岛素分泌,抑制甘蓝释放和慢气排气,从而帮助控制血液凝胶. 甲状腺素的特征是其半衰期延长,允许每星期一次的治疗,使病人方便. 该物质是一种经修改的GLP-1分子组成的混合蛋白质,与人类相连接,有助于其稳定性和血液流中的长期活动. 甲状腺素通常通过亚皮注射来施用,已知具有有利的安全特征,包括胃肠扰动. 它的动作机制不仅有助于血清控制,而且会促进体重损失,这对许多糖尿病患者有利. 但是,对于病人来说,它是至关重要的,在使用这种药物的同时,需要咨询保健专业人员,以获得个人咨询和监测.

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      海关参考信息

      专利信息


      专利号:US-12351573-B2
      优先权日:2019-05-09
      标 题:Compounds for use in synthesis of peptidomimetics
      发明人:AL-ABED YOUSEF; CHENG KAI FAN
      权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
      摘要:Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.

      专利号:US-2023159450-A1
      优先权日:2020-05-08
      标 题 :Dimers for use in synthesis of peptidomimetics
      发明人:AL-ABED YOUSEF; ALTITI AHMAD
      权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
      摘要:Dimers for use in synthesis of peptidomimetics are described. Uses of dimers as synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the dimers and uses of azapeptides and other peptidomimetics are also described.

      专利号:US-2023212216-A1
      优先权日:2019-12-20
      标 题:Synthesis of lactone derivatives and their use in the modification of proteins
      发明人:MORRIS ALEXANDER REDFERN; SUTOV GRIGORIJ; BRUNE KARL DIETRICH
      权利人:GENIE BIOTECH UK LTD
      摘要:Site-specific modifications of proteins are desirable in biotechnological applications such as biopharmaceuticals, immunotherapy, vaccines, and are useful in chemical biology. Gluconoylation is a non-enzymatic, covalent, post-translational modification commonly observed on N-terminal His-Tags bearing proteins. We synthesized glucono-1,5-lactone derivatives, including azido variants for selective acylation. High yield acylation is achieved by simply mixing derivatives with target protein amidst diverse conditions of temperatures, aqueous buffers, excipients, or complex cell lysate.

      专利号:WO-2023105497-A1
      优先权日:2021-12-10
      标题:Synthesis of glp-1 analogues
      发明人:GODHA ATUL KASTURCHAND; NARAYANASWAMY SATHYA VANGANUR; BHAGYARAJ ARETI VENKATA; BAVADEKAR ASLAM JAHANGIR; LAKSHMANAPPA RUDRESH; NAGOOR SHEIKSYEDALI; MURUGAN RANJITHKUMAR; GADAKH AMOL VASANTRAO; SAMBASIVAM GANESH
      权利人:ANTHEM BIOSCIENCES PVT LTD
      摘要:The present invention provides a method of preparation of GLP-1 peptides by using different peptide fragments having amino acid sequences SEQ ID NO:1 (Fragment IG), SEQ ID NO:2 (Fragment SG), Fragment BG, SEQ ID NO:3, and SEQ ID NO:4 5 and combinations thereof. The method of preparation is environmentally benign, simple, straightforward, and efficient and provides the end product in high yield and purity. The purification method of the peptides is also described.

      专利号:US-2024400552-A1
      优先权日:2016-11-11
      标题 :Heterocyclic modulators of lipid synthesis
      发明人:BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
      权利人:SAGIMET BIOSCIENCES INC
      摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

      专利号:US-11622968-B2
      优先权日:2011-03-08
      标 题:Heterocyclic modulators of lipid synthesis
      发明人:BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
      权利人:SAGIMET BIOSCIENCES INC
      摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      合成参考文献


      摘要:Hurren KM et al; Ann Pharmacother 46(5): 710-7 (2012).
      摘要:American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 3128
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知